Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.